Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

---

Dogan B. A., Arduc A., Tuna M. M., Berker D., Demirci N., Demirtas S., ...More

ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, vol.16, no.1, pp.47-55, 2016 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 16 Issue: 1
• Publication Date: 2016
• Doi Number: 10.2174/1871530316666160229120142
• Journal Name: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.47-55
• Gazi University Affiliated: Yes

Abstract

Aim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma.